OphthalmologyNews.net

Ophthalmology Xagena

The clinical and demographic profile of uveitis-related ocular hypertension ( OHT ) was studied and risk factors predisposing to development of ocular hypertension in uveitis were evaluated. Two ...


The aim of a study was to assess the clinical response to Golimumab ( Simponi ) in patients with non-infectious uveitis from a single centre that had previously been treated with other anti-TNF-alpha ...


A study has assessed the safety and efficacy of Tocilizumab ( Actemra; RoActemra ) in patients with severe and refractory non-infectious uveitis. Eight consecutive unselected patients with severe a ...


Long-term daily multivitamin supplement use may lower cataract risk in men, according to a study of nearly 15,000 male physicians published in Ophthalmology, the journal of the American Academy of Oph ...


A new study published in the Journal of the American Association for Pediatric Ophthalmology and Strabismus ( AAPOS ) suggests that the biologic agent Adalimumab ( Humira ) may be a viable treatment o ...


The aim of the GEFAL trial was to evaluate the relative efficacy and safety profile of Bevacizumab ( Avastin ) versus Ranibizumab ( Lucentis ) intravitreal injections for the treatment of neovascular ...


Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ...


The aim of a study was to assess the efficacy of Adalimumab ( Humira ) in patients with active non-infectious uveitis in three different centres. In a retrospective study researchers have identifie ...


The EMA’s Committee for Medicinal Products for Human Use ( CHMP ) has recommended marketing authorisation for Jetrea, a medicinal product indicated for the treatment of adults with vitreomacular tract ...


Results for VEGF Trap-Eye ( Aflibercept ophthalmic solution ) from the Phase 3 MYRROR study in myopic choroidal neovascularization ( mCNV ) were presented. Patients receiving VEGF Trap-Eye at a dose o ...


Tumour necrosis factor ( TNF ) blockers have been demonstrated to be effective in the treatment of systemic and ocular inflammatory diseases. Researchers have conducted a prospective, multicentre, o ...


The experimental drug Selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma.The findings are potentially practice-changing f ...


Nonetheless biologic modifier therapies are available treatment strategies for sight-threatening uveitis in children, the lack of evidence from head-to-head randomized controlled studies limits our un ...


Regeneron has announced that detailed one-year results from the VIEW 1 and VIEW 2 phase 3 studies of Aflibercept ( Eylea ) injection, published in the journal Ophthalmology. Eylea, for the treatmen ...


Corticosteroids are the mainstay of treatment for immune-mediated diseases, including non-infectious uveitis and ocular inflammation, because they are inexpensive, potent and rapidly effective. Howeve ...


Taking oral antiviral medications following infection with the herpes simplex virus may be associated with a reduced risk of recurring eye-related manifestations of the disease.Herpes simplex virus ( ...


All three commonly used TNF blockers ( Infliximab, Etanercept and Adalimumab ) were initially approved for the treatment of rheumatoid arthritis, and were subsequently approved for a number of other s ...


People whose diet includes a lot of red meat are more likely to develop the early stages of an eye condition known as age-related macular degeneration ( AMD ), which is the leading cause of vision los ...


A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms — and improved vision — following treatment with the drug Rituximab MabThera, Rituxan ). Infla ...


Researchers from Boston University School of Medicine ( BUSM ) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati